Molecular characterization of HER2-negative breast cancers reveals a distinct patient subgroup with 17q12 deletion and heterozygous loss of ERBB2.
Qiu X, Tarantino P, Li R, Grinshpun A, Gupta H, Hughes ME, Kirkner G, Scholl L, Johnson BE, Meyerson M, Cherniack AD, Jiang Y, Zhou N, Lin NU, Long HW, Tolaney SM, Jeselsohn R.
Qiu X, et al. Among authors: lin nu.
ESMO Open. 2025 Jan 17;10(2):104111. doi: 10.1016/j.esmoop.2024.104111. Online ahead of print.
ESMO Open. 2025.
PMID: 39826477
Free article.